Payment overview · 2025
General Payments
$923.60
34 reported records · 13 companies
Healthcare provider profile · identity verified
Victoria Greblya, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WESTMINSTER, CA · NPI 1790720969
Verified facts
What the public records show
CMS Open Payments records show Victoria Greblya, MD received $923.60 in general payments during 2025 across 34 reported records.
Madrigal Pharmaceuticals accounted for 41.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $385.05 | 41.7% | 13 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $179.21 | 19.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.04 | 6.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.18 | 6.1% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $51.88 | 5.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.91 | 4.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.88 | 3.7% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $24.95 | 2.7% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $24.28 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.16 | 2.2% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $19.20 | 2.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.31 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.55 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $823.61 | 33 |
| Education | $99.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $385.05 | 13 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $79.22 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.04 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $51.88 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $37.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 287 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 74 |
| Losartan Potassium | Losartan Potassium | 169 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 35 |
| Allopurinol | Allopurinol | 138 | 32 |
| Omeprazole | Omeprazole | 127 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 31 |
| Lisinopril | Lisinopril | 111 | 34 |
| Gabapentin | Gabapentin | 106 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 26 |
| Alprazolam | Alprazolam | 103 | 20 |
| Metformin Hcl | Metformin Hcl | 97 | 30 |
| Donepezil Hcl | Donepezil Hcl | 92 | 24 |
| Simvastatin | Simvastatin | 90 | 24 |
| Sertraline Hcl | Sertraline Hcl | 78 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 20 |
| Celecoxib | Celecoxib | 76 | 27 |
| Azelastine Hcl | Azelastine Hcl | 74 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 16 |
| Furosemide | Furosemide | 71 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 23 |
| Ozempic | Semaglutide | 69 | 15 |
| Eliquis | Apixaban | 66 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 11 |
| Ibuprofen | Ibuprofen | 61 | 13 |
| Metformin Hcl Er | Metformin Hcl | 61 | 17 |
| Meloxicam | Meloxicam | 60 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 12 |
| Carvedilol | Carvedilol | 53 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 13 |
| Ezetimibe | Ezetimibe | 53 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 11 |
| Jardiance | Empagliflozin | 48 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 11 |
| Spironolactone | Spironolactone | 48 | 17 |
| Benazepril Hcl | Benazepril Hcl | 47 | 14 |
| Baclofen | Baclofen | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 12 |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Lorazepam | Lorazepam | 42 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | suppressed |
| Famotidine | Famotidine | 33 | 11 |
| Procto-Med Hc | Hydrocortisone | 33 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | 11 |
| Valsartan | Valsartan | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 23 |
| Mupirocin | Mupirocin | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Prolia | Denosumab | 25 | 16 |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Belsomra | Suvorexant | 18 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $923.60 · 34 records | Madrigal Pharmaceuticals | Briviact, CAPVAXIVE, DUPIXENT, GARDASIL 9, ImmunoCAP, JARDIANCE, Kerendia, LEQVIO, LUMRYZ, MOUNJARO, OTEZLA, REPATHA, REZDIFFRA, Veozah, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error